Kristy Broman, M.D., MPH, an assistant professor in the UAB Department of Surgery’s Division of Surgical Oncology and a member of the UAB Institute for Cancer Outcomes and Survivorship, recently joined UAB MedCast alongside colleagues John Dubay, M.D., Ph.D., and Venkatesh Krishnasamy, M.D., to discuss percutaneous hepatic perfusion (PHP) for metastatic uveal melanoma.
The episode explores how PHP, a liver-directed therapy delivering high-dose melphalan chemotherapy directly to the liver, offers a promising new approach for patients whose metastatic disease is primarily hepatic. PHP allows concentrated treatment of liver metastases while minimizing systemic toxicity, and it is now being offered at UAB through coordinated, multidisciplinary care.
“This is an exciting time for innovation,” Broman said during the episode. “We’re able to offer more precise and personalized treatment options by working closely across specialties.”
In addition to sharing the clinical criteria and procedural logistics for PHP candidacy, Broman emphasized the critical importance of surveillance in patients previously treated for localized uveal melanoma. Because metastases may present years later, continued follow-up ensures early detection and access to novel therapies like PHP.
The conversation also highlighted UAB’s collaborative model for cancer care, with PHP integrated through joint efforts by surgical oncology, interventional radiology, medical oncology and anesthesia. This multidisciplinary effort ensures patients are evaluated comprehensively and receive coordinated care tailored to their disease progression and overall health.